RxDoctor Payments Data

Janet Smith, MD

Cardiovascular Disease · Louisville, KYNPI 1114954625

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by Merck at 57.6% of the total. Reporting peaked in 2019 at $1,009 and has fallen 85.9% since, to $142 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in KY, where the typical reported total is $2,503.

$1,438in general payments, 2019–2025

Across 22 payments — averaging $65.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$829
  • Abiomed$127
  • Medtronic$120
  • Boston Scientific$117
  • Kestra Medical Technology Services, Inc.$65
  • Novartis$57
  • plus $123 from 5 others
$108,515in research payments, 2019–2025

Across 88 payments — averaging $1233.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim Pharma GmbH & Co.kg$51K
  • Boehringer Ingelheim International GmbH$20K
  • Merck$19K
  • AstraZeneca$18K

What the payments were for

  • Travel & lodging$64044%
  • Food & beverage$79856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,438 in reported general payments places this provider in the 35th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$12,554
Medicare patients
88
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$13,537

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →